


Research in Your Backyard

Developing Cures, Creating Jobs



Dots show locations of clinical trials in the state.

**PHARMACEUTICAL
CLINICAL TRIALS IN
COLORADO**

PhARMA

Executive Summary

This report shows that biopharmaceutical research companies continue to be vitally important to the economy and patient health in Colorado, despite the recession.

At a time when the state still faces significant economic challenges, biopharmaceutical research companies are conducting or have conducted more than 3,000 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals. Of the more than 3,000 clinical trials, 1,427 target or have targeted the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses and stroke.**

What are Clinical Trials?

In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration to approve treatments. Clinical tests of new drugs are conducted in three phases and account for seven of the 10 to 15 years required for drug development and approval.

Clinical trials involve thousands of volunteer patient participants, the generation of tens of thousands of pages of technical and scientific data and are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.

Quite often, biopharmaceutical companies hire local research institutions to conduct the tests and in Colorado, they help to bolster local economies in communities

all over the state, including Boulder, Colorado Springs, Denver, Grand Junction and Lakewood.

“The University of Colorado (CU) plays a major role in clinical research. CU is one of a handful of universities that has created four different drugs that have been approved for marketing. CU also has created 18 different drugs currently undergoing clinical trials. Additionally, six CU created drugs have been approved for clinical trials, and 44 drugs are in various stages of pre-clinical trials. CU clinicians are also active in conducting clinical trials. For example, for the 2 month period between January 5, 2012 and March 5, 2012, CU was seeking volunteers for 50 different and newly initiated clinical trials. These clinical related activities address a wide array of human maladies and provide significant economic activity for the State of Colorado.”

—David N. Allen, Ph.D.
University of Colorado Associate Vice President for
Technology Transfer

For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them. More than 280 of the trials underway in Colorado are still recruiting patients.

Participants in clinical trials can:

- Play an active role in their health care.
- Gain access to new research treatments before they are widely available.
- Obtain expert medical care at leading health care facilities during the trial.
- Help others by contributing to medical research.

Patient Safety in Clinical Trials

- All tests must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.
- Clinical trial progress reports must be submitted at least annually to the Food and Drug Administration and the IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

Many different entities and individuals contribute to the safe and appropriate conduct of clinical research, including not only sponsoring companies but also regulatory agencies; investigative site staff and medical professionals who serve as clinical investigators; hospitals and other institutions where research is conducted; and institutional review boards and ethics committees.

Clinical Trials in Colorado since 1999— Completed and Active	
All Clinical Trials	Six Major Chronic Diseases
3,044	1,427

Source: www.clinicaltrials.gov

Note: Search criteria = Colorado, Phase I, II, III; industry only.
Search performed 3/4/2012.

Local Involvement

Colorado institutions involved in clinical tests of treatments include medical schools, research centers and hospitals, such as:

- **Catholic Health Initiatives**, Colorado Springs
- **National Jewish Health**, Denver
- **Storms Clinical Research Institute**, Colorado Springs
- **Children’s Hospital**, Aurora
- **Denver Health Medical Center**, Denver
- **University of Colorado-Denver School of Medicine**, Aurora
- **Memorial Hospital**, Colorado Springs
- **St. Mary’s Regional Cancer Center**, Grand Junction
- **Medical Center of the Rockies**, Fort Collins

The biopharmaceutical research companies working with these institutions have targeted disease wisely—about half of Colorado’s new medicine clinical trials are aimed at chronic conditions that plague patients all over the state, including cancer, diabetes, heart disease and stroke.

There are 281 clinical trials recruiting patients all over the state. These trials target the top six chronic diseases—**asthma, cancer, diabetes, heart disease, mental illness and stroke.**

Equally as important is the fact that many of the medicines being clinically tested here are new-generation biotechnology treatments. With biotechnology, we have the potential to develop safer and more effective therapies and we can improve our ability to predict, preempt or even prevent disease.

Economic Impact of Biopharmaceutical Companies

“The Biopharmaceutical industry in Colorado is a vital part of Colorado’s economy. This sector includes approximately 300 companies employing over 5,410 with average salaries of \$93,000. Not only are these high paying high tech jobs but each are working on the innovative life saving medicines of the future.”

—Holli Riebel
President and CEO, Colorado BioScience Association

Earlier reports show biopharmaceutical research companies have been an important source of research spending:

- A study by Archstone Consulting found that in 2008 biopharmaceutical research firms that year also invested \$379.9 million in research and development and provided \$10.8 billion in products and services.

Clinical Trials in Colorado Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Arvada	0	0	2	1	0	1
Aurora	0	97	14	5	7	1
Centennial	4	1	0	0	0	0
Colorado Springs	10	13	11	11	4	2
Denver	10	97	20	11	27	3
Englewood	1	6	0	1	1	1
Fort Collins	0	4	1	4	0	0
Grand Junction	0	10	0	0	0	0
Highlands Ranch	0	0	0	0	3	0
Lone Tree	0	8	0	1	0	1
Loveland	0	1	0	1	0	0
Wheat Ridge	5	0	1	3	0	1

Source: www.clinicaltrials.gov
 Note: Search criteria = Colorado, Phase I, II; industry only. Search performed 3/4/2012. See Appendix for detailed information about these clinical trials.
 Disease columns will not add to totals in Appendix because some clinical trials are recruiting in more than one city.

The Need for New Chronic Disease Medicines

“Compared to life a few decades ago, people with asthma today have a far better quality of life and greatly reduced risk of morbidity. This is primarily due to research which has already produced a wide array of medicines that help patients control their asthma. Given these improvements, much of the general public may view asthma as an inconvenience, and certainly not as a life-threatening condition. Many would be surprised to hear that asthma still causes over 3400 deaths per year in the U.S., and is a leading cause of absence from school and work. Going forward, it is vitally important that research continue on asthma medications, both to increase their efficacy and to minimize side effects. Colorado is fortunate to have outstanding research institutions that are uniquely poised to continue this important work.”

—Curt Huber
Executive Director, American Lung Association in Colorado

Chronic diseases pose the greatest threats to our nation’s health and our ability to treat and prevent medical conditions. According to the Centers for Disease Control and Prevention, today, in the United States:

- Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.
- Chronic diseases are the **leading cause of death and disability**.
- Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.

With the stakes so high, America’s biopharmaceutical research companies are developing new medicines to help

treat those conditions that are taking an unprecedented toll on American lives.

Many of these medicines are being tested today in clinical trials throughout Colorado.

At a time when tens of thousands of state residents are suffering from one or more chronic diseases, America’s biopharmaceutical research companies are sponsoring or have sponsored 1,427 clinical trials of potential new medicines in the Centennial State alone for **asthma, cancer, heart disease, stroke, diabetes and mental illnesses**. Of the 1,427 trials, 281 are either not yet recruiting or are just now seeking Colorado patients, giving those still searching for effective treatments potential new options and new hope.

Many of the state’s clinical tests involve collaborations with such respected local institutions as the **University of Colorado-Denver School of Medicine**, the **Children’s Hospital Colorado** in Aurora, the **Denver Health Medical Center** in Denver, the **Medical Center of the Rockies** in Fort Collins and **St. Mary’s Regional Cancer Center** in Grand Junction.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	108	17
Cancer	763	173
Diabetes	207	38
Heart Disease	103	18
Mental Illness	229	30
Stroke	17	5
Total	1,427	281

Source: www.clinicaltrials.gov
Note: Search criteria = Colorado, Phase I, II, III; industry only.
Search performed 3/4/2012.

Clinical Trials in Colorado

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines when used by patients. The Food and Drug Administration (FDA) is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	108	17
Cancer	763	173
Diabetes	207	38
Heart Disease	103	18
Mental Illness	229	30
Stroke	17	5
Total	1,427	281

Source: www.clinicaltrials.gov

Note: Search criteria = Colorado, Phase I, II, III; industry only.
Search performed 3/4/2012.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Colorado, biopharmaceutical companies have the luxury of having trials conducted at the states' well-respected university medical schools, comprehensive cancer centers and clinical trial research centers. According to *U.S. News and World Report*, **University of Colorado-Denver School of Medicine** ranked 38th among this year's top 100 research-oriented medical schools in the United States.

Asthma is a debilitating condition for more than 24 million Americans, including 7 million children under the age of 18. In Colorado, about 6.6 percent of adults had asthma and 9.1 percent of children suffered from asthma, according to the Colorado Department of Public Health and Environment.

Currently, 17 clinical trials of new asthma medicines are recruiting patients in Colorado. Trials are being conducted at **National Jewish Health** in Denver (*U.S. News & World Report* named National Jewish Health the #1 respiratory hospital in the nation), the **Rocky Mountain Center for Clinical Research** in Wheat Ridge, and **Storms Clinical Research Institute** in Colorado Springs.

Cancer, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In Colorado, more than 22,000 new cancer cases will be diagnosed this year and 7,190 victims in the state will die, according to the American Cancer Society.

Currently, 173 clinical trials of new cancer medicines are recruiting patients in Colorado. Biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Children's Hospital Center for Cancer and Blood Disorders** and the **University of Colorado-Denver School of Medicine** in Aurora, **St. Mary's Regional Cancer Center** in Grand Junction, the **Rocky Mountain Cancer Center** in Denver, and **Memoorial Hospital** in Colorado Springs.

Diabetes affects more than 25 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In Colorado, about 5.3 percent of adults (or one in 19) have been diagnosed with diabetes, according to the Colorado Department of Public Health and Environment.

Currently, 38 diabetes clinical tests are seeking patients in Colorado. Trials are being conducted at the **Barbara**

Davis Center for Childhood Diabetes and the **University of Colorado Hospital** in Aurora, and **Denver Health** in Denver.

Heart disease and stroke are the first and fourth leading disease causes of death in the United States and the first and third in Colorado. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In Colorado, cardiovascular diseases accounts for about 30 percent of all deaths in the state, according to the Colorado Department of Public Health and Environment.

Currently, 18 heart disease and five stroke clinical tests are seeking patients in Colorado. The trials are being conducted at the **Swedish Medical Center** in Englewood, the **University of Colorado** in Denver, and the **Medical Center of the Rockies** in Fort Collins.

Mental illness affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In Colorado, more than 158,000 adults live with serious mental illness and about 52,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 30 clinical trials are recruiting patients in Colorado. The trials are taking place at **Western Affiliated Research Institute**, **Addiction Research and Treatment Services** and **Radiant Research** in Denver, **Colorado Clinical Trials** in Highlands Ranch, and **Western Affiliated Research Institute** in Denver.

Physicians and patients can find out about clinical trials being conducted all over the state in collaboration with local institutions by accessing www.clinicaltrials.gov, a database sponsored by the National Institutes of Health. Information on medicines in development is also available on www.phrma.org, the website of the Pharmaceutical Research and Manufacturers of America (PhRMA).

New Generation Medicines in Development

Many of the medicines being tested in Colorado are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And Colorado is one of the states where new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict, preempt and prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is

being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at Colorado medical schools and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and Colorado research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in Colorado benefits patients, the state's economy and the advancement of science and patient care. Clinical trial business is good business for the state's medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, Coloradans contemplating participation in clinical trials have a wide range of choices—more than 281 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers.

The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials							
Discovery/ Preclinical Testing		Phase I	Phase II	Phase III	FDA	Phase IV	
Years	6.5	1.5	2	3.5	1.5		
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA	
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use			
Success Rate	5,000 compounds evaluated		5 enter trials		1 approved		

The Drug Development and Approval Process

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug

Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests usually involve about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and

hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 21 new therapeutics approved by the FDA in 2010 was 14.8 months.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. Pharmaceutical companies invested an estimated \$67.4 billion in research and development in 2010.

The Good News – Many Clinical Trials are Still Recruiting

There are 282 clinical trials recruiting in Colorado. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and Coloradans.

Clinical Trials in Colorado Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Arvada	0	0	2	1	0	1
Aurora	0	97	14	5	7	1
Centennial	4	1	0	0	0	0
Colorado Springs	10	13	11	11	4	2
Denver	10	97	20	11	27	3
Englewood	1	6	0	1	1	1
Fort Collins	0	4	1	4	0	0
Grand Junction	0	10	0	0	0	0
Highlands Ranch	0	0	0	0	3	0
Lone Tree	0	8	0	1	0	1
Loveland	0	1	0	1	0	0
Wheat Ridge	5	0	1	3	0	1

Source: www.clinicaltrials.gov

Note: Search criteria = Colorado, Phase I, II, III; industry only. Search performed 3/4/2012. See Appendix for detailed information about these clinical trials. Disease columns will not add to totals in Appendix because some clinical trials are recruiting in more than one city.

The Good News—Many Clinical Trials are Still Recruiting

(continued)

Asthma—Leading Institutions Conducting Clinical Trials

Asthma and Allergy Associates, Colorado Springs
Colorado Allergy and Asthma Centers, Denver
IMMUNOe International Research Center, Centennial
National Jewish Health, Denver
Rocky Mountain Center for Clinical Research,
Wheat Ridge
Storms Clinical Research Institute, Colorado Springs

Cancer—Leading Institutions Conducting Clinical Trials

Catholic Health Initiatives, Colorado Springs
Children’s Hospital Colorado Center for Cancer and
Blood Disorders, Aurora
Colorado Blood Cancer Institute, Denver
Colorado Neurological Institute, Englewood
Denver CyberKnife, Lone Tree
Denver Health Medical Center, Denver
Eastern Colorado Health Care System, Denver
Front Range Cancer Specialists, Fort Collins, Loveland
Genitourinary Surgical Consultants, Denver
IMMUNOe International Research Center, Centennial
Kaiser Permanente Oncology Hematology Clinic,
Denver
Memorial Cancer Medicine Specialists, Colorado
Springs
Memorial Hospital, Colorado Springs
Penrose Cancer Center, Colorado Springs
Rocky Mountain Blood and Morrow Transplant
Program, Denver
Rocky Mountain Cancer Center-Midtown, Denver
St. Mary’s Regional Cancer Center, Grand Junction
The Urology Center of Colorado, Denver

University of Colorado Cancer Center, Aurora
University of Colorado/Anschutz Medical Campus,
Aurora
Urology Associates, Englewood

Diabetes—Leading Institutions Conducting Clinical Trials

Barbara Davis Center for Childhood Diabetes, Aurora
Creekside Endocrine Associates, Denver
Denver Health and Hospital Authority, Denver
Denver Internal Medicine Group, Denver
University of Colorado Denver Health Sciences Center,
Aurora
University of Colorado Hospital-Anschutz Outpatient
Pavilion, Aurora
Western Nephrology and Metabolic Bone Disease,
Arvada

Heart Disease and Stroke—Leading Institutions Conducting Clinical Trials

Aurora Denver Cardiology, Denver
Colorado Cardiac Alliance, Colorado Springs
Denver Health and Hospital Authority, Denver
Medical Center of the Rockies, Fort Collins
Swedish Medical Center, Englewood
University of Colorado, Denver

Mental Illness—Leading Institutions Conducting Clinical Trials

Addiction Research and Treatment Services, Denver
Colorado Clinical Trials, Highlands Ranch
Radiant Research, Denver
Western Affiliated Research Institute, Denver

Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto www.clinicaltrials.gov, the clinical tests database of the National Institutes of Health.

Asthma

(17 clinical trials recruiting)

Study 1:

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

<http://ClinicalTrials.gov/show/NCT01479621>

Study 2:

Safety Study in Adolescent and Adult Patients With Asthma

<http://ClinicalTrials.gov/show/NCT01476904>

Study 3:

Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

<http://ClinicalTrials.gov/show/NCT01312961>

Study 4:

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

<http://ClinicalTrials.gov/show/NCT01172821>

Study 5:

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

<http://ClinicalTrials.gov/show/NCT00941798>

Study 6:

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

<http://ClinicalTrials.gov/show/NCT01285323>

Study 7:

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

<http://ClinicalTrials.gov/show/NCT01238861>

Study 8:

Dose Finding Study for QAW039 in Asthma

<http://ClinicalTrials.gov/show/NCT01437735>

Study 9:

A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

<http://ClinicalTrials.gov/show/NCT01136382>

Study 10:

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

<http://ClinicalTrials.gov/show/NCT01472757>

Study 11:

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma I

<http://ClinicalTrials.gov/show/NCT01172808>

Study 12:

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

<http://ClinicalTrials.gov/show/NCT01287039>

Study 13:

A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

<http://ClinicalTrials.gov/show/NCT00809757>

Study 14:

A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma

<http://ClinicalTrials.gov/show/NCT01402986>

Study 15:

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

<http://ClinicalTrials.gov/show/NCT01270464>

Study 16:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008410>

Study 17:

Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

<http://ClinicalTrials.gov/show/NCT01008423>

Cancer

(173 clinical trials recruiting)

Study 1:

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01217697>

Study 2:

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

<http://ClinicalTrials.gov/show/NCT00925600>

Study 3:

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

<http://ClinicalTrials.gov/show/NCT01077154>

Study 4:

ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01244191>

Study 5:

Study of PX-866 and Docetaxel in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01204099>

Study 6:

Dose-escalation Study of Oral CX-4945

<http://ClinicalTrials.gov/show/NCT00891280>

Study 7:

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01200992>

Study 8:

A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

<http://ClinicalTrials.gov/show/NCT01246960>

Study 9:

Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

<http://ClinicalTrials.gov/show/NCT00320710>

Study 10:

Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01284348>

Study 11:

Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse

<http://ClinicalTrials.gov/show/NCT00849667>

Study 12:

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00643318>

Study 13:

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

<http://ClinicalTrials.gov/show/NCT01314118>

Study 14:

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01126736>

Study 15:

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00840749>

Study 16:

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00876395>

Study 17:

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01126749>

Study 18:

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM2)

<http://ClinicalTrials.gov/show/NCT01234857>

Study 19:

Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01374425>

Study 20:

A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT00762034>

Study 21:

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01297491>

Study 22:

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

<http://ClinicalTrials.gov/show/NCT01204749>

Study 23:

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

<http://ClinicalTrials.gov/show/NCT00676507>

Study 24:

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

<http://ClinicalTrials.gov/show/NCT00858364>

Study 25:

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01188187>

Study 26:

Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

<http://ClinicalTrials.gov/show/NCT01487863>

Study 27:

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01075048>

Study 28:

A Study in Second Line Non Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01168973>

Study 29:

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT00959127>

Study 30:

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01431391>

Study 31:

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT01007942>

Study 32:

Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

<http://ClinicalTrials.gov/show/NCT00721409>

Study 33:

A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

<http://ClinicalTrials.gov/show/NCT01469793>

Study 34:

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01082549>

Study 35:

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

<http://ClinicalTrials.gov/show/NCT01492101>

Study 36:

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or Nab-Paclitaxel

<http://ClinicalTrials.gov/show/NCT01192165>

Study 37:

Combination With Gemcitabine in Advanced Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01251640>

Study 38:

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

<http://ClinicalTrials.gov/show/NCT01449461>

Study 39:

A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01288911>

Study 40:

Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01454102>

Study 41:

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

<http://ClinicalTrials.gov/show/NCT00979134>

Study 42:

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

<http://ClinicalTrials.gov/show/NCT01358877>

Study 43:

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

<http://ClinicalTrials.gov/show/NCT01120184>

Study 44:

A Study in Head and Neck Cancer

<http://ClinicalTrials.gov/show/NCT01081041>

Study 45:

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT00975182>

Study 46:

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

<http://ClinicalTrials.gov/show/NCT00696072>

Study 47:

A Trial In Patients With Advanced Cancer And Leukemia

<http://ClinicalTrials.gov/show/NCT00878189>

Study 48:

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT01004224>

Study 49:

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

<http://ClinicalTrials.gov/show/NCT01338012>

Study 50:

Immunotherapy Study for Surgically Resected Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01072981>

Study 51:

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01395017>

Study 52:

Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01137968>

Study 53:

A Study in Second Line Metastatic Colorectal Cancer

<http://ClinicalTrials.gov/show/NCT01183780>

Study 54:

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01427946>

Study 55:

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

<http://ClinicalTrials.gov/show/NCT01269346>

Study 56:

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

<http://ClinicalTrials.gov/show/NCT01427933>

Study 57:

A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

<http://ClinicalTrials.gov/show/NCT00951665>

Study 58:

A Trial of E7080(Lenvatinib) in 131I-Refractory Differentiated Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01321554>

Study 59:

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01193244>

Study 60:

Study of Immunotherapy to Treat Advanced Prostate Cancer

<http://ClinicalTrials.gov/show/NCT00861614>

Study 61:

International, Multi-Center, Open Label, Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01252693>

Study 62:

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01308567>

Study 63:

A Study Of Combined C-MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01121575>

Study 64:

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01101334>

Study 65:

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Human Papillomavirus Negative Head & Neck Cancer

<http://ClinicalTrials.gov/show/NCT01384799>

Study 66:

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy

<http://ClinicalTrials.gov/show/NCT01419197>

Study 67:

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IIIb-IV KRAS-mutant Non-small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01362296>

Study 68:

Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT01347866>

Study 69:

A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

<http://ClinicalTrials.gov/show/NCT00585195>

Study 70:

A Study of Onartuzumab (MetMAB) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01496742>

Study 71:

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

<http://ClinicalTrials.gov/show/NCT01461538>

Study 72:

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

<http://ClinicalTrials.gov/show/NCT01116271>

Study 73:

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01311713>

Study 74:

Study of EZN-2208 Pediatric Patients With Solid Tumors

<http://ClinicalTrials.gov/show/NCT01295697>

Study 75:

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

<http://ClinicalTrials.gov/show/NCT00844649>

Study 76:

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01479465>

Study 77:

A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01472198>

Study 78:

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

<http://ClinicalTrials.gov/show/NCT01360853>

Study 79:

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

<http://ClinicalTrials.gov/show/NCT01254630>

Study 80:

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

<http://ClinicalTrials.gov/show/NCT01520389>

Study 81:

Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

<http://ClinicalTrials.gov/show/NCT01524783>

Study 82:

Study to Assess Safety, Tolerability and PK of AZD1480 Alone or in Comb With Docetaxel in Patients With Solid Tumours

<http://ClinicalTrials.gov/show/NCT01112397>

Study 83:

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01363024>

Study 84:

A Study Of PF-04449913 Administered Alone In Select Solid Tumors

<http://ClinicalTrials.gov/show/NCT01286467>

Study 85:

A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

<http://ClinicalTrials.gov/show/NCT01160744>

Study 86:

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

<http://ClinicalTrials.gov/show/NCT00871559>

Study 87:

A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

<http://ClinicalTrials.gov/show/NCT01270321>

Study 88:

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

<http://ClinicalTrials.gov/show/NCT01405391>

Study 89:

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

<http://ClinicalTrials.gov/show/NCT01074970>

Study 90:

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

<http://ClinicalTrials.gov/show/NCT01283516>

Study 91:

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01090011>

Study 92:

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01357395>

Study 93:

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

<http://ClinicalTrials.gov/show/NCT01450761>

Study 94:

GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors

<http://ClinicalTrials.gov/show/NCT01332604>

Study 95:

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

<http://ClinicalTrials.gov/show/NCT01294670>

Study 96:

Safety, Pharmacokinetics and Clinical Activity of Oral ON 01910.Na in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01168011>

Study 97:

Melphalan and Panobinostat in Treating Patients With Recurrent Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT00743288>

Study 98:

GSK1120212 Rollover Study

<http://ClinicalTrials.gov/show/NCT01376310>

Study 99:

Phase 1 and 2 Study of PX-866 and Cetuximab

<http://ClinicalTrials.gov/show/NCT01252628>

Study 100:

Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

<http://ClinicalTrials.gov/show/NCT01514864>

Study 101:

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

<http://ClinicalTrials.gov/show/NCT01384292>

Study 102:

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

<http://ClinicalTrials.gov/show/NCT01072175>

Study 103:

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

<http://ClinicalTrials.gov/show/NCT01166542>

Study 104:

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

<http://ClinicalTrials.gov/show/NCT01304784>

Study 105:

PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

<http://ClinicalTrials.gov/show/NCT00818441>

Study 106:

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

<http://ClinicalTrials.gov/show/NCT01233375>

Study 107:

IMA901 in Patients Receiving Sunitinib for Advanced/ Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01265901>

Study 108:

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

<http://ClinicalTrials.gov/show/NCT00506142>

Study 109:

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

<http://ClinicalTrials.gov/show/NCT01455493>

Study 110:

Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma

<http://ClinicalTrials.gov/show/NCT01282463>

Study 111:

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

<http://ClinicalTrials.gov/show/NCT01378975>

Study 112:

Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck

<http://ClinicalTrials.gov/show/NCT01458392>

Study 113:

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

<http://ClinicalTrials.gov/show/NCT01002248>

Study 114:

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01353222>

Study 115:

An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

<http://ClinicalTrials.gov/show/NCT00947856>

Study 116:

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01441414>

Study 117:

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01223027>

Study 118:

A Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01217957>

Study 119:

Dose Escalation Study of INK128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

<http://ClinicalTrials.gov/show/NCT01118689>

Study 120:

Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

<http://ClinicalTrials.gov/show/NCT01080391>

Study 121:

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

<http://ClinicalTrials.gov/show/NCT01498952>

Study 122:

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

<http://ClinicalTrials.gov/show/NCT01124786>

Study 123:

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

<http://ClinicalTrials.gov/show/NCT01191801>

Study 124:

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01471782>

Study 125:

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

<http://ClinicalTrials.gov/show/NCT01480479>

Study 126:

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

<http://ClinicalTrials.gov/show/NCT01310816>

Study 127:

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

<http://ClinicalTrials.gov/show/NCT01369329>

Study 128:

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced L-sarcoma

<http://ClinicalTrials.gov/show/NCT01343277>

Study 129:

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

<http://ClinicalTrials.gov/show/NCT01136967>

Study 130:

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

<http://ClinicalTrials.gov/show/NCT01032070>

Study 131:

Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

<http://ClinicalTrials.gov/show/NCT01441635>

Study 132:

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01297244>

Study 133:

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

<http://ClinicalTrials.gov/show/NCT01035229>

Study 134:

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01271803>

Study 135:

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

<http://ClinicalTrials.gov/show/NCT01028222>

Study 136:

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

<http://ClinicalTrials.gov/show/NCT01519323>

Study 137:

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

<http://ClinicalTrials.gov/show/NCT01264380>

Study 138:

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

<http://ClinicalTrials.gov/show/NCT01515189>

Study 139:

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01327885>

Study 140:

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01168791>

Study 141:

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT01327053>

Study 142:

A Study of IMC-3G3 in Soft Tissue Sarcoma

<http://ClinicalTrials.gov/show/NCT01185964>

Study 143:

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01282424>

Study 144:

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

<http://ClinicalTrials.gov/show/NCT00210665>

Study 145:

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

<http://ClinicalTrials.gov/show/NCT01141491>

Study 146:

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

<http://ClinicalTrials.gov/show/NCT00782626>

Study 147:

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

<http://ClinicalTrials.gov/show/NCT01209442>

Study 148:

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

<http://ClinicalTrials.gov/show/NCT00788775>

Study 149:

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

<http://ClinicalTrials.gov/show/NCT01321541>

Study 150:

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

<http://ClinicalTrials.gov/show/NCT00790036>

Study 151:

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

<http://ClinicalTrials.gov/show/NCT00774345>

Study 152:

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

<http://ClinicalTrials.gov/show/NCT01073163>

Study 153:

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01188681>

Study 154:

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

<http://ClinicalTrials.gov/show/NCT01100502>

Study 155:

A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01414205>

Study 156:

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

<http://ClinicalTrials.gov/show/NCT01519011>

Study 157:

Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia

<http://ClinicalTrials.gov/show/NCT01410513>

Study 158:

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

<http://ClinicalTrials.gov/show/NCT00931918>

Study 159:

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

<http://ClinicalTrials.gov/show/NCT00980018>

Study 160:

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

<http://ClinicalTrials.gov/show/NCT01209130>

Study 161:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib

<http://ClinicalTrials.gov/show/NCT00777036>

Study 162:

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

<http://ClinicalTrials.gov/show/NCT01147939>

Study 163:

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

<http://ClinicalTrials.gov/show/NCT01177540>

Study 164:

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

<http://ClinicalTrials.gov/show/NCT01414855>

Study 165:

Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

<http://ClinicalTrials.gov/show/NCT01460160>

Study 166:

A Study of MLN9708 in Adult Patients With Lymphoma

<http://ClinicalTrials.gov/show/NCT00893464>

Study 167:

A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

<http://ClinicalTrials.gov/show/NCT01421667>

Study 168:

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

<http://ClinicalTrials.gov/show/NCT01294579>

Study 169:

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

<http://ClinicalTrials.gov/show/NCT01476787>

Study 170:

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

<http://ClinicalTrials.gov/show/NCT00948090>

Study 171:

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

<http://ClinicalTrials.gov/show/NCT01155817>

Study 172:

A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

<http://ClinicalTrials.gov/show/NCT01411267>

Study 173:

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

<http://ClinicalTrials.gov/show/NCT00941109>

Diabetes

(38 clinical trials recruiting)

Study 1:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

<http://ClinicalTrials.gov/show/NCT01195662>

Study 2:

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)

<http://ClinicalTrials.gov/show/NCT01137474>

Study 3:

BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients

<http://ClinicalTrials.gov/show/NCT01131676>

Study 4:

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

<http://ClinicalTrials.gov/show/NCT01293461>

Study 5:

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01243424>

Study 6:

A Study in Patients With Type I Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01454284>

Study 7:

Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

<http://ClinicalTrials.gov/show/NCT01422876>

Study 8:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01351675>

Study 9:

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01144338>

Study 10:

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

<http://ClinicalTrials.gov/show/NCT01103284>

Study 11:

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 12:

Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01414920>

Study 13:

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT00658021>

Study 14:

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01513473>

Study 15:

A Study in Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01435616>

Study 16:

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01392573>

Study 17:

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

<http://ClinicalTrials.gov/show/NCT00701935>

Study 18:

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01204775>

Study 19:

A Study in Participants With Type 1 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01481779>

Study 20:

A Study in Participants With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01468987>

Study 21:

Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01289990>

Study 22:

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01306214>

Study 23:

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

<http://ClinicalTrials.gov/show/NCT01434186>

Study 24:

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01338870>

Study 25:

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

<http://ClinicalTrials.gov/show/NCT01496430>

Study 26:

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation

<http://ClinicalTrials.gov/show/NCT01179048>

Study 27:

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

<http://ClinicalTrials.gov/show/NCT01445951>

Study 28:

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01069965>

Study 29:

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by 54 Week Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes

<http://ClinicalTrials.gov/show/NCT01183013>

Study 30:

Reversing Type 1 Diabetes After it is Established

<http://ClinicalTrials.gov/show/NCT01106157>

Study 31:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 32:

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Diabetic Patients With Peripheral Arterial Disease-SONIC

<http://ClinicalTrials.gov/show/NCT01401517>

Study 33:

A Study in Patients With Diabetic Kidney Disease

<http://ClinicalTrials.gov/show/NCT01113801>

Study 34:

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

<http://ClinicalTrials.gov/show/NCT00935766>

Study 35:

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

<http://ClinicalTrials.gov/show/NCT01356849>

Study 36:

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

<http://ClinicalTrials.gov/show/NCT01496365>

Study 37:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 38:

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

<http://ClinicalTrials.gov/show/NCT01399580>

Heart Disease

(18 clinical trials recruiting)

Study 1:

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

<http://ClinicalTrials.gov/show/NCT01516541>

Study 2:

Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/ Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs)

<http://ClinicalTrials.gov/show/NCT01464476>

Study 3:

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

<http://ClinicalTrials.gov/show/NCT00935766>

Study 4:

A Study With Alogliptin in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

<http://ClinicalTrials.gov/show/NCT01042769>

Study 5:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 6:

RED-HF™ Trial—Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

<http://ClinicalTrials.gov/show/NCT00358215>

Study 7:

Premium Migraine Trial

<http://ClinicalTrials.gov/show/NCT00355056>

Study 8:

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

<http://ClinicalTrials.gov/show/NCT01130246>

Study 9:

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

<http://ClinicalTrials.gov/show/NCT01313572>

Study 10:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>

Study 11:

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

<http://ClinicalTrials.gov/show/NCT01251406>

Study 12:

Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy

<http://ClinicalTrials.gov/show/NCT01121107>

Study 13:

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

<http://ClinicalTrials.gov/show/NCT01147250>

Study 14:

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

<http://ClinicalTrials.gov/show/NCT01327183>

Study 15:

Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter

<http://ClinicalTrials.gov/show/NCT01401361>

Study 16:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 17:

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

<http://ClinicalTrials.gov/show/NCT01165580>

Study 18:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Mental Illness

(30 clinical trials recruiting)

Study 1:

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

<http://ClinicalTrials.gov/show/NCT01360645>

Study 2:

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

<http://ClinicalTrials.gov/show/NCT01360866>

Study 3:

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

<http://ClinicalTrials.gov/show/NCT01405053>

Study 4:

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

<http://ClinicalTrials.gov/show/NCT00550238>

Study 5:

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00667810>

Study 6:

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

<http://ClinicalTrials.gov/show/NCT01382719>

Study 7:

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01361555>

Study 8:

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01435759>

Study 9:

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

<http://ClinicalTrials.gov/show/NCT00998764>

Study 10:

Vigabatrin for the Treatment of Cocaine Dependency

<http://ClinicalTrials.gov/show/NCT01281202>

Study 11:

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

<http://ClinicalTrials.gov/show/NCT01318434>

Study 12:

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01428661>

Study 13:

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

<http://ClinicalTrials.gov/show/NCT01396447>

Study 14:

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

<http://ClinicalTrials.gov/show/NCT00731549>

Study 15:

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01467700>

Study 16:

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01173601>

Study 17:

A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

<http://ClinicalTrials.gov/show/NCT01187407>

Study 18:

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2)

<http://ClinicalTrials.gov/show/NCT01349907>

Study 19:

Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients

<http://ClinicalTrials.gov/show/NCT01467713>

Study 20:

Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM2)

<http://ClinicalTrials.gov/show/NCT01244815>

Study 21:

Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder

<http://ClinicalTrials.gov/show/NCT01179516>

Study 22:

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

<http://ClinicalTrials.gov/show/NCT01429116>

Study 23:

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

<http://ClinicalTrials.gov/show/NCT01072630>

Study 24:

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01163032>

Study 25:

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01127633>

Study 26:

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01309945>

Study 27:

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

<http://ClinicalTrials.gov/show/NCT01430754>

Study 28:

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

<http://ClinicalTrials.gov/show/NCT01492374>

Study 29:

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

<http://ClinicalTrials.gov/show/NCT01369095>

Study 30:

Cocaine Use Reduction With Buprenorphine

<http://ClinicalTrials.gov/show/NCT01402492>

Stroke

(5 clinical trials recruiting)

Study 1:

Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

<http://ClinicalTrials.gov/show/NCT00856661>

Study 2:

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

<http://ClinicalTrials.gov/show/NCT01225562>

Study 3:

Insulin Resistance Intervention After Stroke Trial

<http://ClinicalTrials.gov/show/NCT00091949>

Study 4:

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities

<http://ClinicalTrials.gov/show/NCT01101035>

Study 5:

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

<http://ClinicalTrials.gov/show/NCT01327846>



Pharmaceutical Research and Manufacturers of America
950 F Street, NW, Washington, DC 20004

www.phrma.org